Cala Health

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™ therapy, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology, and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Cala Health headquartered in United States, North America, operates in the Health Care, Medical, Wearables, Neuroscience sector. The company focuses on Health Care and has secured $9.5B in funding across 64 round(s). With a team of 101-250 employees, Cala Health is actively contributing to advancements in Health Care. Their latest funding round, Series B - Cala Health, raised $18.0M. Discover more about their projects, partnerships, and impact on our platform.